Cargando…
Surveillance nanotechnology for multi-organ cancer metastases
The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different met...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844578/ https://www.ncbi.nlm.nih.gov/pubmed/29531851 http://dx.doi.org/10.1038/s41551-017-0167-9 |
_version_ | 1783305259913838592 |
---|---|
author | Kantamneni, Harini Zevon, Margot Donzanti, Michael J. Zhao, Xinyu Sheng, Yang Barkund, Shravani R. McCabe, Lucas H. Banach-Petrosky, Whitney Higgins, Laura M. Ganesan, Shridar Riman, Richard E. Roth, Charles M. Tan, Mei-Chee Pierce, Mark C. Ganapathy, Vidya Moghe, Prabhas V. |
author_facet | Kantamneni, Harini Zevon, Margot Donzanti, Michael J. Zhao, Xinyu Sheng, Yang Barkund, Shravani R. McCabe, Lucas H. Banach-Petrosky, Whitney Higgins, Laura M. Ganesan, Shridar Riman, Richard E. Roth, Charles M. Tan, Mei-Chee Pierce, Mark C. Ganapathy, Vidya Moghe, Prabhas V. |
author_sort | Kantamneni, Harini |
collection | PubMed |
description | The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different metastatic niches. Here, we show that intravenously injected rare-earth-doped albumin-encapsulated nanoparticles emitting short-wave infrared light (SWIR) can detect targeted metastatic lesions in vivo, allowing for the longitudinal tracking of multi-organ metastases. In a murine model of basal human breast cancer, the nanoprobes enabled whole-body SWIR detection of adrenal gland microlesions and bone lesions that were undetectable via contrast-enhanced magnetic resonance imaging (CE-MRI) as early as, respectively, three weeks and five weeks post-inoculation. Whole-body SWIR imaging of nanoprobes functionalized to differentially target distinct metastatic sites and administered to a biomimetic murine model of human breast cancer resolved multi-organ metastases that showed varied molecular profiles at the lungs, adrenal glands and bones. Real-time surveillance of lesions in multiple organs should facilitate pre-therapy and post-therapy monitoring in preclinical settings. |
format | Online Article Text |
id | pubmed-5844578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-58445782018-06-12 Surveillance nanotechnology for multi-organ cancer metastases Kantamneni, Harini Zevon, Margot Donzanti, Michael J. Zhao, Xinyu Sheng, Yang Barkund, Shravani R. McCabe, Lucas H. Banach-Petrosky, Whitney Higgins, Laura M. Ganesan, Shridar Riman, Richard E. Roth, Charles M. Tan, Mei-Chee Pierce, Mark C. Ganapathy, Vidya Moghe, Prabhas V. Nat Biomed Eng Article The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different metastatic niches. Here, we show that intravenously injected rare-earth-doped albumin-encapsulated nanoparticles emitting short-wave infrared light (SWIR) can detect targeted metastatic lesions in vivo, allowing for the longitudinal tracking of multi-organ metastases. In a murine model of basal human breast cancer, the nanoprobes enabled whole-body SWIR detection of adrenal gland microlesions and bone lesions that were undetectable via contrast-enhanced magnetic resonance imaging (CE-MRI) as early as, respectively, three weeks and five weeks post-inoculation. Whole-body SWIR imaging of nanoprobes functionalized to differentially target distinct metastatic sites and administered to a biomimetic murine model of human breast cancer resolved multi-organ metastases that showed varied molecular profiles at the lungs, adrenal glands and bones. Real-time surveillance of lesions in multiple organs should facilitate pre-therapy and post-therapy monitoring in preclinical settings. 2017-12-12 2017 /pmc/articles/PMC5844578/ /pubmed/29531851 http://dx.doi.org/10.1038/s41551-017-0167-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Kantamneni, Harini Zevon, Margot Donzanti, Michael J. Zhao, Xinyu Sheng, Yang Barkund, Shravani R. McCabe, Lucas H. Banach-Petrosky, Whitney Higgins, Laura M. Ganesan, Shridar Riman, Richard E. Roth, Charles M. Tan, Mei-Chee Pierce, Mark C. Ganapathy, Vidya Moghe, Prabhas V. Surveillance nanotechnology for multi-organ cancer metastases |
title | Surveillance nanotechnology for multi-organ cancer metastases |
title_full | Surveillance nanotechnology for multi-organ cancer metastases |
title_fullStr | Surveillance nanotechnology for multi-organ cancer metastases |
title_full_unstemmed | Surveillance nanotechnology for multi-organ cancer metastases |
title_short | Surveillance nanotechnology for multi-organ cancer metastases |
title_sort | surveillance nanotechnology for multi-organ cancer metastases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844578/ https://www.ncbi.nlm.nih.gov/pubmed/29531851 http://dx.doi.org/10.1038/s41551-017-0167-9 |
work_keys_str_mv | AT kantamneniharini surveillancenanotechnologyformultiorgancancermetastases AT zevonmargot surveillancenanotechnologyformultiorgancancermetastases AT donzantimichaelj surveillancenanotechnologyformultiorgancancermetastases AT zhaoxinyu surveillancenanotechnologyformultiorgancancermetastases AT shengyang surveillancenanotechnologyformultiorgancancermetastases AT barkundshravanir surveillancenanotechnologyformultiorgancancermetastases AT mccabelucash surveillancenanotechnologyformultiorgancancermetastases AT banachpetroskywhitney surveillancenanotechnologyformultiorgancancermetastases AT higginslauram surveillancenanotechnologyformultiorgancancermetastases AT ganesanshridar surveillancenanotechnologyformultiorgancancermetastases AT rimanricharde surveillancenanotechnologyformultiorgancancermetastases AT rothcharlesm surveillancenanotechnologyformultiorgancancermetastases AT tanmeichee surveillancenanotechnologyformultiorgancancermetastases AT piercemarkc surveillancenanotechnologyformultiorgancancermetastases AT ganapathyvidya surveillancenanotechnologyformultiorgancancermetastases AT mogheprabhasv surveillancenanotechnologyformultiorgancancermetastases |